-
Democrats, Trump hold final rallies before midterm elections
-
African players in Europe: Defender Hakimi's historic hat-trick
-
Japan urges US to enforce discipline after second Marine arrest
-
Struggling Slavia face Arsenal as grim record looms
-
'Remarkable' rookie Lendeborg scores 37 as Warriors beat Clippers
-
Vikings suffer first loss while Broncos edge Chiefs in NFL
-
ExxonMobil urged to re-think Papua New Guinea gas project
-
South Korea to double spending on AI and chips in 2027
-
Asian stocks mixed as tech sector struggles to rebound from selloff
-
On All Saints' Day, Philippine mountain town honours dead with fire
-
India's royals find new power in their past
-
Years on from fall of IS, French jihadists face justice in Iraq
-
Irish bookshops help meet UK demand for Sally Rooney novels
-
Point of Law favourite at Australia's 'race that stops a nation'
-
NFL Vikings suffer first loss while Broncos edge Chiefs
-
'Kid' Antonelli gets affectionate tributes from all quarters
-
Host of fresh faces in Australia white-ball squads to face England
-
Hamilton accuses Leclerc of wrecking Ferrari hopes
-
NFL linebacker Campbell to remain hospitalized overnight
-
Chervon Names Jody Grimsley Senior National Account Manager
-
BioLargo's Clyra Medical Gains Commercial Traction as Clinician Enthusiasm Drives Health System Adoption
-
enVVeno Medical to Showcase the enVVe System at 38th Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium
-
Gladstone Alternative Income Fund Announces Monthly Cash Distribution for November 2026
-
Nexscient Announces Expanded Customer Engagements and New Commercial Agreements in Autonomous Driving and Humanoid Robotics Data Services
-
Vicapsys Life Sciences Provides Shareholder Update on VICAPSYN(TM) Program Advancing Toward Phase 1 Human Clinical Trial, Vertically Integrated With the Company's Indian Health Service Strategy
-
XCF Global Withdraws Reverse Stock Split Proposal; Reaffirms Growth Strategy and Shareholder Support
-
Gladstone Commercial Corporation Earnings Call and Webcast Information
-
cbdMD Completes Acquisition of the Operating Assets and Brands of Twinlab, including Twinlab, Reserveage and Metabolife Brands, Expanding Into Broader Wellness
-
Palo Alto Collaboration Company Opens Waitlist for Pana, a Personal AI That Builds Tools That Stay Yours
-
Anthony, Linder & Cacomanolis Recognized in Chambers & Partners Spotlight Florida 2027 for Securities Law Excellence
-
Tectonic Metals Intersects 5.61 g/t Au Over 41.15 m, Including 12.94 g/t Au Over 13.72 m, Within 2.86 g/t Au Over 91.44 m, Strengthening Evidence for a Second Gold System at the Flat Gold Project
-
IRS Pushes Tax Deadlines to February 1, 2027 for Washington Wildfire Counties - Clear Start Tax Explains What the Postponement Does Not Pause
-
Optimistivity Unveils Refreshed Brand and Expanded Digital Product Range
-
GameSquare to Report Q3 2026 Financial Results on November 16, 2026
-
AsiaFIN Holdings Corp. to Host Q3 2026 Earnings Webcast from New York City
-
Predictiv AI Awarded Metrolinx Master Agreement for On-Demand Transit Software and Related Services
-
Electric Metals (USA) Limited Announces Results of Annual Meeting of Stockholders
-
iAsk.ai Surpasses One Billion Searches
-
International Battery Metals Announces Second Quarter Fiscal 2027 Financial Results Conference Call and Webcast
-
Electrovaya Ranks Fourth Among Canada's Enterprise - Industry Leaders in Deloitte's Technology Fast 50(TM) Program
-
BEING rather than HAVING. A fascinating, practical STORY.
-
Hospital AI Funding Faces a Reality Check: New 2027 Outlook Puts Outsourcing Savings to the Test
-
Jaguar Mining Provides Update on Permitting of the Onças de Pitangui Development Project, Minas Gerais, Brazil
-
Ur-Energy Announces Retirement of CFO Roger Smith, Names VP Finance Jade Walle as Successor
-
DataMEDS AI Enters Into Agreement for Commercial Supply of Six Peptides Recommended by FDA Advisory Committee
-
Aer Lingus and MTech Mobility Launch Live Ground Operations Technology Programme Across Three Irish Airports
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 02
-
Bank of San Francisco Reports Third Quarter 2026 Financial Results
-
Aegis Capital Corp. Announces the Hiring of a New Managing Director
-
Foundation Software Announces Keynote Speakers for Its All-User Conference, CONVERGE27
Disgraced surgeon on trial in Sweden over windpipe transplants
An Italian doctor who made headlines for pioneering windpipe surgery went on trial in Sweden on Wednesday, charged with assault for performing the experimental procedure.
Paolo Macchiarini won praise in 2011 after claiming to have performed the world's first synthetic trachea transplants using stem cells while he was a surgeon at Stockholm's Karolinska Institute.
The procedure was hailed as a breakthrough in regenerative medicine.
But allegations soon emerged that the risky procedure had been carried out on at least one person who had not been critically ill at the time of the operation.
The 63-year-old appeared in court in a blue suit Wednesday, where he listened to translated audio as prosecutors listed the charges of "aggravated assault" against three patients.
- 'Disregard for science' -
The Karolinska Institute has confirmed that the three individuals have since died, but did not directly link the deaths to the operations.
"Macchiarini has carried out the surgery with complete disregard for science and tried experience," prosecutor Karin Lundstrom-Kron told the court.
As prosecutors presented their case they referenced both external and internal reviews of the case, including one published in 2016 by physician Kjell Asplund, who argued that Macchiarini should never have been employed by Karolinska in the first place.
"It is clear that this method has not worked," prosecutor Jim Westerberg said, adding that Macchiarini had embellished the benefits of the procedure.
Macchiarini, who took notes without showing much emotion, has maintained the operations constituted treatments and not experiments, and denied being criminally responsible.
"He contends that he has performed health care, cured and helped," Macchiarini's lawyer Bjorn Hurtig told AFP during a recess.
The prosecution's presentation of evidence is expected to continue over several days so the defence will likely not be able to present its side until next week.
But Hurtig said they had "high hopes" they would be able to counter the prosecution's evidence.
"There are quite a lot of gaps in that evidence and there is a lot of evidence that we argue are favourable to our view of things," he said.
- Downplayed risks -
In 2013, the Karolinska hospital suspended all transplants and refused to extend Macchiarini's contract as a surgeon.
A year later, several surgeons at the hospital filed a complaint alleging that Macchiarini had downplayed the risks of the procedure.
Macchiarini carried out three surgeries at Karolinska University Hospital in 2011 and 2012, using an artificial windpipe made of plastic and coating it with the patient's own stem cells.
Together with his colleagues, he performed a total of eight such transplants between 2011 and 2014, the five others taking place in Russia.
An external review in 2015 found Macchiarini guilty of research misconduct, but despite sacking him, the Karolinska Institute repeatedly defended him until 2018, when it found him and several other researchers guilty.
The university's principal stepped down over the scandal, as well as a number of other people.
Medical journal The Lancet in 2018 retracted two papers authored by Macchiarini.
The trial, held in the Solna district court near the Karolinska Institute, is scheduled to take place over 13 days.
J.Williams--AMWN